Falcon Point Capital LLC lowered its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 52.3% during the second quarter, Holdings Channel reports. The firm owned 232,664 shares of the specialty pharmaceutical company’s stock after selling 255,053 shares during the period. Falcon Point Capital LLC’s holdings in Supernus Pharmaceuticals were worth $10,028,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in SUPN. Meeder Asset Management Inc. increased its position in shares of Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 2,315 shares during the period. Ameritas Investment Partners Inc. bought a new position in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $127,000. Fortaleza Asset Management Inc. bought a new position in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $160,000. State of Alaska Department of Revenue increased its position in shares of Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 170 shares during the period. Finally, OppenheimerFunds Inc. bought a new position in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $205,000. Institutional investors own 94.39% of the company’s stock.

Shares of Supernus Pharmaceuticals, Inc. (SUPN) opened at 41.40 on Friday. The stock has a 50 day moving average of $42.47 and a 200 day moving average of $34.12. Supernus Pharmaceuticals, Inc. has a 52 week low of $17.25 and a 52 week high of $44.95. The firm has a market cap of $2.10 billion, a P/E ratio of 20.89 and a beta of 1.31.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The firm had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. Equities analysts forecast that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Falcon Point Capital LLC Has $10.03 Million Position in Supernus Pharmaceuticals, Inc. (SUPN)” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/12/falcon-point-capital-llc-has-10-03-million-position-in-supernus-pharmaceuticals-inc-supn.html.

Several equities analysts have commented on SUPN shares. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a report on Thursday, July 13th. Cantor Fitzgerald increased their price target on Supernus Pharmaceuticals from $34.00 to $49.00 and gave the company a “buy” rating in a report on Wednesday, July 5th. Jefferies Group LLC increased their price target on Supernus Pharmaceuticals from $45.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, June 28th. Stifel Nicolaus reiterated a “buy” rating and set a $47.00 price target (up previously from $36.00) on shares of Supernus Pharmaceuticals in a report on Tuesday, July 18th. Finally, BidaskClub downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $48.43.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 2,556 shares of the company’s stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $44.90, for a total value of $114,764.40. Following the transaction, the vice president now directly owns 24,944 shares of the company’s stock, valued at approximately $1,119,985.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 2,500 shares of the company’s stock in a transaction on Friday, May 26th. The shares were sold at an average price of $35.90, for a total value of $89,750.00. Following the completion of the transaction, the vice president now directly owns 37,500 shares in the company, valued at $1,346,250. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,291 shares of company stock worth $962,766. Insiders own 6.70% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.